You are now leaving the Kedrion website. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NEWS / CORPORATE / .........

CORPORATE - 17-12-2016

IVIg efficacy in chronic inflammatory polyradiculoneuropathy (CIDP)

IVIg efficacy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was tested thanks to Kedrion Biopharma support.

Benefits, initially reported only in observational studies, were later established in randomized controlled trials, and confirmed by the multicentre, randomized, double-blind, placebo-controlled trial coordinated by Professor Nobile Orazio and sponsored by Kedrion. The study compared IVIg administration versus intravenous methilprednysolone in 45 patients with CIDP (Eduardo Nobile-Orazio et al. THE LANCET Neurology 2012).

CIDP is a chronic, debilitating, autoimmune disorder of the peripheral nerves, resulting in a gradually increasing weakness of the legs and, to a lesser extent, of the arms. This disease can occur at any age and in both genders, and its incidence is approximately 4 per 100.000 population. For several years now, Kedrion has been a reliable partner for associations, such as the Peripheral Nerve Society (PNS), the European Academy of Neurology (EAN) and the Italian Association for the study of the peripheral nervous system (ASNP), which work on an international scale to improve patients’ access to treatments for neurological disorders.

For more information please contact: